Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Chronic 2Pheochromocytoma 1Paraganglioma 1Pancreatic Neoplasms 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Kidney Neoplasms 1Gastrointestinal Stromal Tumors 1Gallbladder Neoplasms 1Cholangiocarcinoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Specimen Handling 4lutetium Lu 177 dotatate 3gallium Ga 68 dotatate 3Magnetic Resonance Spectroscopy 3olaparib 2cabozantinib 2belzutifan 2Temozolomide 2Nivolumab 2Fluorodeoxyglucose F18 2Biopsy 2talazoparib 1spartalizumab 1pembrolizumab 1lanreotide 1guadecitabine 1fludarabine phosphate 1copper dotatate CU-64 1atezolizumab 1Phenoxybenzamine 1ONC206 1Lutetium-177 1Lutetium 1Ipilimumab 1Interleukin-13 1Genetic Testing 1Everolimus 1Cyclophosphamide 1Contrast Media 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Paraganglioma × guadecitabine × 1 year × Clear all
NCT03165721 2026-02-18

A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
9 enrolled 11 charts
CNSEndocrineGastrointestinalGenitourinarySarcoma

Carcinoma, Renal Cell, Kidney Neoplasms, Paraganglioma, Pheochromocytoma, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡